Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 황승용 | - |
dc.date.accessioned | 2023-05-31T01:01:10Z | - |
dc.date.available | 2023-05-31T01:01:10Z | - |
dc.date.issued | 2012-06 | - |
dc.identifier.citation | British Journal of Cancer, v. 107, NO. 1, Page. 108-115 | - |
dc.identifier.issn | 0007-0920;1532-1827 | - |
dc.identifier.uri | https://www.nature.com/articles/bjc2012206 | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/181626 | - |
dc.description.abstract | BACKGROUND: Cytosine arabinoside-based chemotherapy coupled with anthracycline is currently the first-line treatment for acute myeloid leukaemia (AML), but diverse responses to the regimen constitute obstacles to successful treatment. Therefore, outcome prediction to chemotherapy at diagnosis is believed to be a critical consideration. METHODS: The mRNA expression of 12 genes closely involved in the actions of cytosine arabinoside and anthracycline was evaluated by real-time reverse transcriptase PCR (RT-PCR), in 54 diagnostic bone marrow specimens of M2-subtype AML. RESULTS: Low expression levels of ribonucleotide reductase M2 (RRM2) and high expression levels of topoisomerase 2 beta (TOP2B) were correlated with longer survival in a univariate analysis. Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P = 0.002) and overall survival (HR, 0.29; P = 0.005). CONCLUSION: Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype. British Journal of Cancer (2012) 107, 108-115. doi: 10.1038/bjc.2012.206 www.bjcancer.com Published online 24 May 2012 (C) 2012 Cancer Research UK | - |
dc.description.sponsorship | the grant A111218-GM06 of the National Project for Personalized Genomic Medicine, Ministry for Health & Welfare and the National Research Foundation of Korea (NRF) grant 2011-0001388 funded by the Korea government. | - |
dc.language | en | - |
dc.publisher | Nature Publishing Group | - |
dc.subject | AML | - |
dc.subject | standard chemotherapy | - |
dc.subject | prognosis | - |
dc.subject | topoisomerase 2 | - |
dc.title | High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia | - |
dc.type | Article | - |
dc.relation.no | 1 | - |
dc.relation.volume | 107 | - |
dc.identifier.doi | 10.1038/bjc.2012.206 | - |
dc.relation.page | 108-115 | - |
dc.relation.journal | British Journal of Cancer | - |
dc.contributor.googleauthor | Song, Ju-han | - |
dc.contributor.googleauthor | Kweon, Sin-ho | - |
dc.contributor.googleauthor | Kim, Hee-je | - |
dc.contributor.googleauthor | Lee, Tae-hyang | - |
dc.contributor.googleauthor | Min, Woo-sung | - |
dc.contributor.googleauthor | Kim, Hyeoung-joon | - |
dc.contributor.googleauthor | Kim, Yeo-kyeoung | - |
dc.contributor.googleauthor | Hwang, Seungyong | - |
dc.contributor.googleauthor | Kim, Taesung | - |
dc.sector.campus | E | - |
dc.sector.daehak | 과학기술융합대학 | - |
dc.sector.department | 의약생명과학과 | - |
dc.identifier.pid | syhwang | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.